An Audience With in 2012

Filter By:

Article Type
Year

  • Roche is one of the few pharmaceutical companies that has stayed firmly committed to research and development for central nervous system disorders. Here, Luca Santarelli, Senior Vice President and Head of Neuroscience Research and Early development, discusses why.

    An Audience With

  • Chris Lipinski, originator of the 'rule of five' guidelines for predicting the oral bioavailability of drug candidates, discusses their impact as well as efforts to expand drug-like chemical space and drug repositioning initiatives.

    An Audience With

  • Garry Neil, acting CEO of TransCelerate, discusses the new precompetitive venture's aims to make clinical trials more efficient.

    An Audience With

  • Michael Snyder, Director of Stanford Center for Genomics and Personalized Medicine, discusses how the ENCODE project could impact drug discovery.

    An Audience With

  • Mark McClellan, Director of the Brookings Institution's health care reform centre, discusses the need for better metrics to measure the health of biomedical innovation.

    An Audience With

  • Jane Reese-Coulbourne, executive director of the Reagan-Udall Foundation, discusses how long-awaited federal funding will be used to support the FDA's regulatory science.

    An Audience With

  • Alan Trounson, President of the California Institute for Regenerative Medicine, discusses his plans to get more stem cell therapeutics into trials.

    An Audience With

  • Gregory Lip, a cardiologist at the University of Birmingham Centre for Cardiovascular Sciences, discusses the changing oral anticoagulant landscape.

    An Audience With

  • Stephen Frye, from the University of North Carolina in Chapel Hill, USA, discusses emerging capabilities of academic drug discoverers.

    An Audience With

  • Trevor Mundel, new President of Global Health at the Bill & Melinda Gates Foundation, discusses his plans for a high-throughput approach to translational research.

    An Audience With

  • Guido Rasi, the recently appointed head of the European Medicines Agency, discusses his goals for the regulatory agency.

    An Audience With

  • RuiPing Dong, head of emerging markets R&D at Merck & Co., discusses the strategy behind the firm's recent US$1.5 billion expansion into China.

    An Audience With

  • Mark Fishman, President of the Novartis Institutes for BioMedical Research, looks back on his past decade of heading up R&D.

    An Audience With